[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617109":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":11,"centralContacts":31,"locations":37,"responsibleParty":75,"collaborators":11,"id":77,"slug":11,"hasResults":78,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":11,"eligibilityCriteria":82,"healthyVolunteers":83,"sex":84,"minAge":85,"maxAge":86,"enrollmentInfo":87,"targetDuration":11,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":11,"overallStatus":40,"whyStopped":11,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Atea Pharmaceuticals, Inc.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"(n=16) buprenorphine\u002Fnaloxone + BEM\u002FRZR","EXPERIMENTAL",null,[13],"Drug: Buprenorphine\u002FNaloxone + BEM\u002FRZR",{"label":15,"type":10,"description":11,"interventionNames":16},"(n=16) methadone + BEM\u002FRZR",[17],"Drug: Methadone +BEM\u002FRZR",[19,26],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Buprenorphine\u002FNaloxone + BEM\u002FRZR","Day -5 to Day -1:buprenorphine\u002Fnaloxone as individualized QD doses up to 24mg\u002F6mg.\n\nDay 1 to Day 5:Individualized QD doses of buprenorphine\u002Fnaloxone. Day 6 to Day 12:Individualized QD doses of buprenorphine\u002Fnaloxone + BEM 550mg\u002FRZR 180mg QD.\n\nDay 13 Individualized QD doses of buprenorphine\u002Fnaloxone.",[9],[25],"BEM (AT-527)\u002FRZR (AT-038)",{"type":20,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Methadone +BEM\u002FRZR","Day -5 to Day -1:methadone individualized QD doses: 30-150mg. Day 1 to Day 5:Individualized QD does of methadone. Day 6 to Day 12:Individualized QD doses of methadone + BEM 550mg\u002FRZR 180mg QD. Day 13 Individualized QD doses of methadone.",[15],[25],[32],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},"Atea Study Clinical Trials Administrator","CONTACT","888-481-1607","ateaclinicaltrials@ateapharma.com",[38,53,64],{"facility":39,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Atea Study Site","RECRUITING","Hollywood","Florida","33019","United States",{"type":46,"coordinates":47},"Point",[48,49],-80.14949,26.0112,{"lat":49,"lon":48},[52],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"facility":39,"status":40,"city":54,"state":55,"zip":56,"country":44,"cosmosGeoPoint":57,"geoPoint":61,"contacts":62},"Overland Park","Kansas","66212",{"type":46,"coordinates":58},[59,60],-94.67079,38.98223,{"lat":60,"lon":59},[63],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"facility":39,"status":40,"city":65,"state":66,"zip":67,"country":44,"cosmosGeoPoint":68,"geoPoint":72,"contacts":73},"Marlton","New Jersey","08053",{"type":46,"coordinates":69},[70,71],-74.92183,39.89122,{"lat":71,"lon":70},[74],{"name":33,"role":34,"phone":35,"phoneExt":11,"email":36},{"type":76,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100617109",false,"NCT07314346","Drug-drug Interaction Study of Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone","A Phase 1, Open-Label, Two-Part, Single-Sequence Study to Evaluate the Effect of Multiple Oral Doses of BEM\u002FRZR FDC on the Pharmacokinetics of Buprenorphine\u002FNaloxone or Methadone in Participants on Stable Maintenance Therapy for Opiate Withdrawal","Inclusion Criteria:\n\n* Must agree to use acceptable contraceptive methods through at least 90 days after the last dose of study drug.\n* Minimum body weight of 50 kg and body mass index (BMI) of 18-32 kg\u002F m2.\n* Willing to comply with the study requirements and to provide written informed consent.\n\nExclusion Criteria:\n\n* Infected with hepatitis B virus, hepatitis C virus, HIV.\n* Abuse of alcohol or drugs.\n* Use of other investigational drugs within 28 days prior to Day -5.\n* Concomitant use of prescription medications, or systemic over-the-counter medications (apart from methadone or buprenorphine\u002Fnaloxone as assigned maintenance therapy).\n* Other clinically significant medical conditions or laboratory abnormalities.",true,"ALL","18 Years","65 Years",{"count":88,"type":89},32,"ESTIMATED","INTERVENTIONAL",[92],"PHASE1","Drug-drug interaction study between Bemnifosbuvir\u002FRuzasvir (BEM\u002FRZR) and Buprenorphine\u002FNaloxone or Methadone",[95],"Healthy Volunteer Study","2026-04-08",{"date":98,"type":99},"2026-04-13","ACTUAL",{"date":101,"type":99},"2025-01-07",{"date":103,"type":89},"2026-06",{"name":5,"class":6},3]